Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LABA · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Controlled asthma | EXPERIMENTAL | - |
| Uncontrolled asthma with additional OCS | EXPERIMENTAL | - |
| Uncontrolled asthma without additional OCS | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| LABA | DRUG | long-acting beta-agonist treatment |
| corticosteroids | DRUG | chronic treatment with oral corticosteroids, high dose inhaled corticosteroids |
| prednisolone | DRUG | additional 0.5 mg/kg orally for 7 days |
Inclusion Criteria: * Adult and adolescent patients , \>/=12 to \</=75 years of age at the time of informed consent * Severe asthma (as defined by GINA step 5 classification of asthma severity) after a detailed systematic assessment (the BTS UK Difficult Asthma Network assessment model \[Heaney et ...
LABA is a small molecule being investigated for the treatment of asthma. It is currently in Phase 2 clinical development, meaning it is still investigational and has not been approved for use. The drug is being studied in patients with severe asthma who are dependent on oral corticosteroids.
LABA is being developed by Roche Holding AG, a biopharmaceutical company traded under the ticker RHHBY. The drug is currently in Phase 2 clinical development for the treatment of asthma, and it is still in the investigational stage.
LABA is in Phase 2 clinical development for asthma. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The Phase 2 trial for LABA has been completed, and the drug remains under clinical investigation.
LABA has one completed Phase 2 clinical trial registered under NCT01948401. The study, titled "A Study to Measure Serum Periostin, Asthma-Related Biomarkers and Response to Prednisolone in Adult and Adolescent Patients With Severe Oral Corticosteroid-Dependent Asthma," enrolled 54 participants in the United Kingdom.
LABA is the abbreviation for long-acting beta agonist, a class of medications used to treat asthma. In this context, LABA refers to a specific small molecule drug being developed by Roche Holding AG for asthma. It is currently in Phase 2 clinical development and remains investigational.